The advances in the understanding and management of vascular — and cardiovascular — diseases over the past 50 years now empower cardiologists and other specialists with many options to achieve target outcomes. A succinct chapter, Â “Cell Therapy for Cardiovascular Disease” in the book, “Advances in Vascular Medicine”, highlights cell therapy’s growing role:
Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades.1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types – the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell – as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.
Â FromÂ linkÂ
More than a dozen companies have cell therapy products on the market for treatment of cardiovascular and vascular diseases. Â (SeeÂ Report #S520Â from MedMarket Diligence.) Â Many more have products actively in development at the preclinical and clinical stage, with products nearing U.S. and European approval.